血管紧张素Ⅱ促进内皮细胞凋亡和NOX4表达

目的分析高浓度血管紧张素Ⅱ（AngⅡ）刺激人脐静脉内皮细胞（HUVECs）时细胞内活性氧（ROS）、NOX4mRNA水平和细胞凋亡的变化。方法倒置显微镜下观察人脐静脉内皮细胞形态;免疫组化法检测人脐静脉内皮细胞Ⅷ因子相关抗原的表达;RT—PCR检测HUVECs中NOX4的表达;流式细胞仪检测各组细胞内ROS生成量和细胞凋亡率,Hoechst染色分析细胞凋亡。结果高AngⅡ刺激HUVECs时,NOX4mRNA表达上调,细胞内ROS生成增加,细胞凋亡增加。结论高AngⅡ上调HUVCEs内NOX4mR—NA表达并促进细胞内ROS生成和细胞凋亡。     

MicroRNA-21介导非对称性二甲基精氨酸诱导的内皮细胞衰老

目的：观察非对称性二甲基精氨酸（ADMA）对内皮细胞中microRNA-21（miR-21）表达的影响,探讨microRNA-21在ADMA诱导的内皮细胞衰老中的作用。方法：人脐静脉内皮细胞（HUVEC）与10uM的ADMA孵育48小时后收集细胞提取总RNA及蛋白,荧光定量实时RT—PCR检测miR-21表达,Westernblot检测超氧化物歧化酶2（SOD2）表达,衰老相关半乳糖苷酶（SA-β-gal）染色鉴定衰老的内皮细胞;然后HUVEC与miR-21抑制剂转染6小时后继续与10uM的ADMA孵育48小时留取细胞按上述方法检测相关指标。结果：HUVEC与ADMA孵育后miR-21表达量明显增加（P〈0．01）,同时衰老的内皮细胞数量增多（P〈0．05）,而SOD2表达减少（P〈0．01）;MiR-21抑制剂转染HUVEC后ADMA诱导的miR-21表达明显减少,同时衰老的内皮细胞减少,而SOD2表达明显增加（所有P〈0．01）。结论：ADMA诱导了HUVEC中miR-21表达及细胞衰老,miR-21介导了ADMA诱导的内皮细胞衰老作用,其机制可能与其抑制SOD2表达有关。     

瘦素对血管平滑肌细胞周期蛋白D1、CDK2表达的影响

目的观察瘦素对人平滑肌细胞周期时相及cyclin D1、CDK2表达的影响,探讨瘦素促进平滑肌细胞增殖的作用机制。方法取对数生长期的平滑肌细胞同步于G0期,分为加入浓度为0、20、40、80、100、200ng/ml瘦素的各组。作用24h后分别用MTT法检测细胞活性,用流式仪进行细胞周期时相的检测,Western blot法测定Cyclin D1、CDK2的表达。结果随着瘦素浓度的增加G0/G1期的平滑肌细胞逐渐减少,S期和G2/M期细胞逐渐增加,PI增殖指数逐渐增加。cyclin D1、CDK2蛋白的表达呈剂量依赖性的上升趋势。以上两项检测均在100ng/ml处达最高。结论瘦素上调cyclinD1、CDK2蛋白的表达,可能是促进平滑肌细胞增殖的机制之一。     

内皮抑素对人脐静脉内皮细胞(HUVEC) 及体外微血管 模型的作用及其可能的机制

目的：探讨内皮抑素对人脐静脉内皮细胞（HUVEC）及体外微血管模型的作用及其可能的机制。方法：1．MTT法检测不同浓度（10～50μg／ml）内皮抑素作用72h和30μg／ml内皮抑素作用不同时间（24～72h）对HUVEC细胞的影响;2、电镜观察HUVEC细胞超微结构的变化;3．光镜下观察内皮抑素（30μg／ml）对体外人造血管模型的影响。结果：1．MTT检测显示,内皮抑素（20～50μg／ml）能抑制HUVEC细胞的增殖（P〈0．05,P〈0．01）,具有剂量-时间依赖性。2．电镜观察,HUVEC细胞内皮抑素作用组均出现凋亡改变。3．光镜观察,内皮抑素能抑制新生血管的形成,并能破坏新生的血管网。结论：内皮抑素能抑制人脐静脉血管内皮细胞HUVEC的增殖,并具有时间一剂量依赖性,机制可能为诱导细胞凋亡。提示,内皮抑素可能通过诱导HUVEC的凋亡抑制其增殖,并能破坏新生的血管。内皮抑素可能以此抑制机体肿瘤的生长与转移。     

GW501516通过TGFβ-Smad3信号途径促进人脐静脉内皮细胞PAI-1的表达

为探讨过氧化物酶体增殖物激活型受体δ(peroxisome proliferator-activated receptor-δ,PPARδ)激动剂GW501516对人脐静脉内皮细胞纤溶酶原激活物抑制剂1(PAI-1)表达的影响及机制,采用siRNA、TGFβ-Smad3信号通路阻滞剂等处理细胞,经实时定量PCR、Western blot方法分别检测细胞中PAI-1及磷酸化Smad3蛋白的表达.结果显示,与对照组比较,GW501516可诱导人脐静脉内皮细胞(HUVEC)中PAI-1表达,且此效应呈浓度和时间依赖性(P0.05);siRNA沉默PPARδ的表达后,可阻抑GW501516对HUVEC细胞PAI-1表达的促进作用;TGFβ-Smad3信号通路抑制剂SB-431542与SIS3均可降低HUVEC细胞pSmad3蛋白的表达,而细胞PAI-1表达也随之降低.结果提示,GW501516可促进HUVEC细胞PAI-1的表达,其机制可能与TGFβ-Smad3信号通路有关.     

原儿茶酸促进人脂肪干细胞体外增殖的研究

为了寻找能够促进干细胞增殖的药物,观察了中药益智仁（Alpinia oxyphylln）中提取的原儿茶酸对人脂肪干细胞体外增殖的影响,并对其作用机制进行了初步的探讨．人脂肪干细胞能在体外分化为神经元样细胞,并对凋亡的PC-12细胞起到保护作用．原儿茶酸能够促进人脂肪干细胞的增殖,且呈现明显的剂量依赖性和时间依赖性．流式细胞术检测细胞DNA含量的结果显示,原儿茶酸处理组细胞S期所占比例明显增加,其中,1．5mmol／L原儿茶酸处理组细胞S期所占比例与对照组相比增加2倍以上．同时,该组细胞G2／M期所占比例明显增加,G0／G1期所占比例明显下降．蛋白质免疫印迹结果显示,1．5mmol／L原儿茶酸处理组细胞周期素D1（cyclinD1）的表达明显升高．cyclin D1-siRNA转染显著抑制了原儿茶酸对人脂肪干细胞体外增殖的促进作用．流式细胞术检测细胞表面标志物,成骨诱导和脂肪诱导的结果显示,原儿茶酸处理后,人脂肪干细胞仍保持间充质干细胞多分化潜能的特性．上述结果提示,原儿茶酸有可能在人脂肪干细胞介导的干细胞移植治疗中发挥作用．     

十五肽BPC-157对人脐静脉内皮细胞功能的影响

目的:观察十五肽BPC-157对人脐静脉内皮细胞株HUVEC增殖、周期、迁移及小管形成的影响。方法:用不同浓度(0、1、5、10、50、100μg/mL)的BPC-157作用于HUVEC细胞株,采用MTT法检测药物对内皮细胞增殖的影响,通过流式细胞仪观察细胞周期的变化,经细胞划痕和Transwell实验检测药物对内皮细胞迁移的影响,并且通过小管形成实验观察BPC-157对内皮细胞小管形成能力的影响。结果:HUVEC细胞株经BPC-157刺激48 h后,细胞增殖率和各时期细胞比例没有明显变化;而在刺激12 h时,BPC-157显著性促进细胞伤口愈合及穿膜细胞数的增加(P0.01);刺激8 h时,给药组细胞开始聚合,形成复杂的管状网络结构,特别是5μg/mL剂量组。结论:十五肽BPC-157对人脐静脉内皮细胞株HUVEC增殖及细胞周期的改变基本没有影响,但对内皮细胞的迁移及小管形成能力具有明显的促进作用。     

麦冬不同提取物对过氧化氢损伤人血管内皮细胞ICAM-1、VEGF、Bcl-2表达的影响

目的：观察麦冬不同提取物对过氧化氢诱导的人脐静脉内皮细胞（HUVEC）间黏附分子-1（ICAM-1）和VEGF、Bcl-2表达的影响。方法：体外培养HUVEC,用过氧化氢（H2O2）制造HUVEC损伤模型。以四甲基偶氮唑蓝（MTT）比色法检测细胞存活数量,用流式细胞仪检测HUVEC表面ICAM-1的表达量;免疫细胞化学方法检测HUVEC的VEGF、Bcl-2的分布情况。结果：模型组较正常对照组细胞增殖活性明显降低（P〈0．01）。与模型组相比,经麦冬水提物、正丁醇提取物处理组细胞增殖活性明显增加（P〈0．05,P〈0．01）。流式细胞仪检测显示正丁醇提取物可降低过氧化氢增加的ICAM-1基因的表达。Bcl-2的表达,模型组明显低于正常对照组,而正丁醇组表达明显高于模型组（P〈0．01）。VEGF的表达,模型组明显高于正常对照组,麦冬水提物、正丁醇提取物处理组高于模型纽（P〈0．05,P〈0．01）。结论：麦冬提取物具有抗凋亡、促增殖、降低细胞间黏附分子-1表达的作用,尤以正丁醇提取物效果更为显著。     

人脐静脉血管内皮细胞的分离、培养、鉴定及试验研究

血管内皮细胞体外培养,在血管再生、新血管生成机理、内皮细胞在心血管系统疾病中的作用、内皮细胞与造血的关系等方面的研究中有很高的应用价值。本研究借鉴了前人的工作,建立了胶原酶灌流消化获得人脐静脉血管内皮细胞并进行体外培养的方法,探讨了影响人脐静脉血管内皮细胞（HUVEC）分离培养的影响因素。同时应用建立的HUVEC体外培养进行了内皮抑素的抑制活性检测,证明了内皮抑素对于激活增殖的HUVEC的抑制作用,为今后的试验研究打下了基础。     

天然和氧化低密度脂蛋白对人脐静脉内皮细胞VCAM-1表达的影响

目的探讨天然和氧化低密度脂蛋白(n-LDL,ox-LDL)对人脐静脉内皮细胞(HUVEC)VCAM-1表达的影响。方法将n-LDL,ox-LDL作用于培养的HUVEC,用细胞酶联免疫吸附试验(cellELISA)检测VCAM-1蛋白的表达,用原位分子杂交技术检测VCAM-1 mRNA的表达。结果正常培养的HUVEC可表达VCAM-1,n-LDL和ox-LDL均可增强培养的HUVEC表达VCAM-1,尤以ox-LDL作用更明显。结论n-LDL、ox-LDL可能通过促进血管内皮细胞表达VCAM-1而在动脉粥样硬化的早期事件中起作用。     

Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo

Formononetin is one of the main components of red clover plants, and is considered as a typical phytoestrogen. This study further investigated that formononetin inactivated IGF1/IGF1R-PI3K/Akt pathways and decreased cyclin D1 mRNA and protein expression in human breast cancer cells in vitro and in vivo. MCF-7 cells were treated with different concentrations of formononetin. The proliferation of the cells treated with formononetin was tested by MTT assay. The cell cycle in the treated cells was examined by flow cytometry. The levels of p-IGF-1?R, p-Akt, and cyclin D1 protein expression and cyclin D1?mRNA expression in the treated cells were determined by Western blot and RT-PCR, respectively. In addition, the antitumor activity of formononetin was evaluated in nude mice bearing orthotopic tumor implants. Compared with the control, formononetin inhibited the proliferation of MCF-7 cells and effectively induced cell cycle arrest. The levels of p-IGF-1?R, p-Akt, cyclin D1 protein expression, and cyclin D1?mRNA expression were also downregulated. On the other hand, formononetin also prevented the tumor growth of human breast cancer cells in nude mouse xenografts. These results show that formononetin causes cell cycle arrest at the G0/G1 phase by inactivating IGF1/IGF1R-PI3K/Akt pathways and decreasing cyclin D1?mRNA and protein expression, indicating the use of formononetin in the prevention of breast cancer carcinogenesis.     

桦木酸对人胃癌SGC-7901细胞增殖的影响*

目的:利用不同浓度的桦木酸对人胃癌SGC-7901细胞增殖的影响。方法:桦木酸设4个不同浓度(0、10、20、30 μg/ml),并采用常规化疗药物5-Fu处理作为阳性对照,以探究其对细胞增殖的影响。采用台盼蓝拒染法和吉姆萨染色法分别检测桦木酸对人胃癌SGC-7901细胞生长抑制率及克隆形成率;EdU法检测SGC-7901的细胞增殖;利用流式细胞术检测细胞周期, 应用qRT-PCR和Western blot分别检测细胞周期蛋白cyclin D1,cyclin B1的mRNA和蛋白表达水平。结果:不同浓度的桦木酸处理人胃癌SGC-7901细胞48 h后,其细胞生长抑制率显著升高(P＜0.05),克隆形成率和细胞增殖率均明显降低(P＜0.01),且呈剂量和时间依赖性;人胃癌SGC-7901细胞被阻滞在G1/G0期,细胞周期蛋白cyclin D1和cyclin B1的mRNA和蛋白表达量也随桦木酸浓度升高而显著降低(P＜0.01)。且与5-Fu对照组相比,桦木酸浓度为20 μg/ml和30 μg/ml时,细胞增殖能力明显降低,细胞周期被抑制,细胞周期蛋白表达量均明显降低(P ＜0.05)。结论:桦木酸通过下调cyclin B1和cyclin D1基因表达,将人胃癌SGC-7901细胞阻滞在G1/G0期,从而抑制细胞增殖。     

RNA干扰Ｃyclin D1基因表达对瘢痕疙瘩成纤维细胞增殖和G1期调控的影响

为研究siRNA干扰瘢痕疙瘩成纤维细胞cyclin D1基因表达,对瘢痕疙瘩成纤维细胞的增殖、细胞周期和G1期调控的影响,构建了靶向cyclin D1的siRNA表达质粒.利用LipofecmmineTM2000转染体外培养的瘢痕疙瘩成纤维细胞,应用荧光定量PCR、RT-PCR检测cyclin D1 mRNA的干扰效果,应用MTT法、流式细胞仪检测细胞增殖和细胞周期的变化,应用免疫组织化学染色检测成纤维细胞中cyclin D1、CDK4、P16、pRb蛋白表达的影响.主要结果如F:a.靶向cyclin D1的特异性siRNA序列可以高效地抑制成纤维细胞cyclin D1基因表达,对照组与实验组在mRNA水平其表达抑制率分别为63.68%和92.83%(P<0.01);b.可以显著抑制瘢痕疙瘩成纤维细胞的增殖,改变细胞周期分布,G0/G1期细胞比例显著高于各对照组(P<0.05),细胞分裂被阻滞;c.免疫组化染色发现,转染72 h后,过表达的cyclin D1、CDK4和pRb蛋白,在瘢痕疙瘩成纤维细胞中均出现了不同程度的表达下调,而低表达的P16则呈上调表现.由上述结果可见,构建的靶向cyclin D1的RNAi表达质粒,可有效地抑制瘢痕疙瘩成纤维细胞cyclin D1基因表达,通过改变Gl期相关周期蛋白的水平,影响G1/S期的进程,显著地抑制成纤维细胞的增殖.     

PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression

PDK1 (3-phosphoinositide-dependent protein kinase 1) is a key mediator of signaling by phosphoinositide 3-kinase. To gain insight into the physiological importance of PDK1 in cell proliferation and cell cycle control, we established immortalized mouse embryonic fibroblasts (MEFs) from mice homozygous for a "floxed" allele of Pdk1 and from wild-type mice. Introduction of Cre recombinase by retrovirus-mediated gene transfer resulted in the depletion of PDK1 in Pdk1(lox/lox) MEFs but not in Pdk1(+/+) MEFs. The insulin-like growth factor-1-induced phosphorylation of various downstream effectors of PDK1, including Akt, glycogen synthase kinase 3, ribosomal protein S6, and p70 S6 kinase, was markedly inhibited in the PDK1-depleted (Pdk1-KO) MEFs. The rate of serum-induced cell proliferation was reduced; progression of the cell cycle from the G(0)-G(1) phase to the S phase was delayed, and cell cycle progression at G(2)-M phase was impaired in Pdk1-KO MEFs. These cells also manifested an increased level of p27(Kip1) expression and a reduced level of cyclin D1 expression during cell cycle progression. The defect in cell cycle progression from the G(0)-G(1) to the S phase in Pdk1-KO MEFs was rescued by forced expression of cyclin D1, whereas rescue of the defect in G(2)-M progression in these cells required both overexpression of cyclin D1 and depletion of p27(Kip1) by RNA interference. These data indicate that PDK1 plays an important role in cell proliferation and cell cycle progression by controlling the expression of both cyclin D1 and p27(Kip1).     

Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells

Arsenic trioxide (As2O3, diarsenic oxide) has recently been reported to induce apoptosis and inhibit the proliferation of various human cancer cells derived from solid tumors as well as hematopoietic malignancies. In this study, the in vitro effects of As2O3 and tetraasrsenic oxide (As4O6) on cell cycle regulation and basic fibroblast growth factor (bFGF)- or vascular endothelial growth factor (VEGF)-stimulated cell proliferation of human umbilical vein endothelial cells (HUVEC) were investigated. Significant dose-dependent inhibition of cell proliferation was observed when HUVEC were treated with either arsenical compound for 48 h, and flow cytometric analysis revealed that these two arsenical compounds induced cell cycle arrest at the G1 and G2/M phases--the increases in cell population at the G1 and G2/M phase were dominantly observed in As2O3- and As4O6-treated cells, respectively. In both arsenical compounds-treated cells, the protein levels of cyclin A and CDC25C were significantly reduced in a dose-dependent manner, concomitant to the reduced activities of CDK2- and CDC2-associated kinase. In G1-synchronized HUVEC, the arsenical compounds prevented the cell cycle progression from G1 to S phase, which was stimulated by bFGF or VEGF, through the inhibition of growth factor-dependent signaling. These results suggest that arsenical compounds inhibit the proliferation of HUVEC via G1 and G2/M phase arrest of the cell cycle. In addition, these inhibitory effects on bFGF- or VEGF-stimulated cell proliferation suggest antiangiogenic potential of these arsenical compounds.     

孕激素诱导cyclin G1在小鼠子宫内膜上皮细胞的表达及其对细胞增殖的影响

本文在体外培养条件下研究卵巢激素诱导小鼠子宫内膜上皮细胞cyclin G1的表达及细胞增殖和细胞周期进程的变化,以探讨孕激素依赖的细胞周期调控因子cyclin G1对子宫内膜上皮细胞增殖的负调控作用.原代培养小鼠子宫内膜上皮细胞,待其生长汇合后分为4组:对照组(C组)、雌激素组(E组)、孕激素组(P组)、雌、孕激素共同作用组(EP组).加入相应激素作用24 h后,用细胞免疫化学方法检测各组细胞cyclin G1的表达水平:四甲基偶氮唑蓝(MTT)比色法检测各组细胞活力,间接观察子宫内膜上皮细胞的增殖情况;用流式细胞仪检测分布在细胞周期各时相的子宫内膜上皮细胞所占百分数.细胞免疫化学结果显示,cyclin G1在C组和E组子宫内膜上皮细胞上无明显表达,而在P组和EP组子宫内膜上皮细胞中表达明显,且定位于细胞核内.MTT法结果显示,与C组相比,E组细胞活力明显增高,而P组和EP组的细胞活力均明显下降,表明雌激素能促进子宫内膜上皮细胞增殖,而孕激素则具有抑制子宫内膜上皮细胞增殖的作用.流式细胞术检测显示,与C组相比,E组中处于S期的子宫内膜上皮细胞百分数增多;P组与EP组中处于S期的子宫内膜上皮细胞百分数明显减少,而处于G1期的细胞百分数和G2/M期的细胞百分数则明显增加.上述结果提示,孕激素依赖的cyclin G1可能通过阻滞细胞周期进程来参与孕激素对子宫内膜上皮细胞增殖的负调控作用.     

Fibronectin promotes cell cycle entry in smooth muscle cells in primary culture

Smooth muscle cell proliferation after arterial injury is regulated by growth factors and components of the extracellular matrix. We have previously demonstrated that fibronectin promotes a phenotypic modulation of freshly isolated rat smooth muscle cells from a contractile to a synthetic phenotype in primary culture and supports the ability of the cells to respond to growth factors. Here, we analyzed if fibronectin promotes cell cycle entry in freshly isolated rat aortic smooth muscle cells during primary culture. Cell cycle analysis showed that cells seeded on fibronectin remained in the G(0)/G(1) phase of the cell cycle during the first 6 days of culture. During this period, there was an increased expression of cyclin D1 and p27(KIP1) in the absence of exogenous growth factors. Addition of serum was followed by enhanced cyclin D1 expression, decreased p27(KIP1) levels, hyperphosphorylation of Rb protein, induction of cyclin A and cyclin D3 expression, and cell cycle progression into S phase. The results indicate that fibronectin initiates cell cycle entry in freshly isolated smooth muscle cells by promoting the induction of cyclin D1 and thereby facilitates further cell cycle progression together with growth factors.     

Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line

Arginine vasopressin (AVP) is a nonapeptide long known as an endocrine and paracrine regulator of important systemic functions, namely, vasoconstriction, gluconeogenesis, corticosteroidogenesis, and excretion of water and urea. Here we report, for the first time, that AVP specifically inhibits expression of the cyclin D1 gene, leading to cell cycle blockage and halting cell proliferation. In G0/G1-arrested mouse Y1 adrenocortical tumor cells, maintained in serum-free medium (SFM), AVP mimics FGF2, promoting rapid ERK1/2 activation (5 min) followed by c-Fos protein induction (2 h). PKC inhibitor Go6983 and PI3K inhibitors wortmannin and LY294002 all inhibit ERK1/2 activation by AVP, but not by FGF2. Thus, AVP and FGF2 concur to activate ERK1/2 by different regulatory pathways. However, AVP is not a mitogenic factor for Y1 cells. On the contrary, AVP strongly antagonizes FGF2 late induction (2-5 h) of the cyclin D1 gene, down-regulating both cyclin D1 mRNA and protein. AVP inhibition of cyclin D1 expression is sufficient to block G1 phase progression and cell entry into the S phase, monitored by BrdU nuclear labeling. In addition, AVP completely inhibits proliferation of Y1 cells in 10% fetal calf serum (10% FCS) medium. On the other hand, ectopic expression of the cyclin D1 protein renders Y1 cells resistant to AVP for both entry into the S phase in SFM and continuous proliferation in 10% FCS medium. In conclusion, inhibition of cyclin D1 expression by AVP is an efficient mechanism of cell cycle blockage and consequent proliferation inhibition in Y1 adrenocortical cells.     

Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Cyclins and proto-oncogenes including c-myc have been implicated in eukaryotic cell cycle control. The role of cyclins in steroidal regulation of cell proliferation is unknown, but a role for c-myc has been suggested. This study investigated the relationship between regulation of T-47D breast cancer cell cycle progression, particularly by steroids and their antagonists, and changes in the levels of expression of these genes. Sequential induction of cyclins D1 (early G1 phase), D3, E, A (late G1-early S phase), and B1 (G2 phase) was observed following insulin stimulation of cell cycle progression in serum-free medium. Transient acceleration of G1-phase cells by progestin was also accompanied by rapid induction of cyclin D1, apparent within 2 h. This early induction of cyclin D1 and the ability of delayed administration of antiprogestin to antagonize progestin-induced increases in both cyclin D1 mRNA and the proportion of cells in S phase support a central role for cyclin D1 in mediating the mitogenic response in T-47D cells. Compatible with this hypothesis, antiestrogen treatment reduced the expression of cyclin D1 approximately 8 h before changes in cell cycle phase distribution accompanying growth inhibition. In the absence of progestin, antiprogestin treatment inhibited T-47D cell cycle progression but in contrast did not decrease cyclin D1 expression. Thus, changes in cyclin D1 gene expression are often, but not invariably, associated with changes in the rate of T-47D breast cancer cell cycle progression. However, both antiestrogen and antiprogestin depleted c-myc mRNA by > 80% within 2 h. These data suggest the involvement of both cyclin D1 and c-myc in the steroidal control of breast cancer cell cycle progression.